NCT01244984 - A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma | Biotech Hunter

Enrollment

243

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Asthma

Interventions

DRUG

Fluticasone Furoate/GW642444 Inhalation Powder

Fluticasone Furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks

DRUG

Fluticasone Furoate Inhalation Powder

Fluticasone Furoate inhalation powder inhaled orally once daily for 52 weeks

Trial Locations (30)

277-0863

GSK Investigational Site, Chiba

802-0083

GSK Investigational Site, Fukuoka

816-0813

GSK Investigational Site, Fukuoka

501-6062

GSK Investigational Site, Gifu

373-0021

GSK Investigational Site, Gunma

730-0844

GSK Investigational Site, Hiroshima

732-0062

GSK Investigational Site, Hiroshima

739-0402

GSK Investigational Site, Hiroshima

665-0827

GSK Investigational Site, Hyōgo

670-0046

GSK Investigational Site, Hyōgo

672-8064

GSK Investigational Site, Hyōgo

302-0022

GSK Investigational Site, Ibaraki

231-8682

GSK Investigational Site, Kanagawa

253-0041

GSK Investigational Site, Kanagawa

601-1495

GSK Investigational Site, Kyoto

615-8087

GSK Investigational Site, Kyoto

983-0824

GSK Investigational Site, Miyagi

983-8520

GSK Investigational Site, Miyagi

390-0303

GSK Investigational Site, Nagano

390-8510

GSK Investigational Site, Nagano

700-0862

GSK Investigational Site, Okayama

701-0304

GSK Investigational Site, Okayama

714-0081

GSK Investigational Site, Okayama

545-8586

GSK Investigational Site, Osaka

569-1192

GSK Investigational Site, Osaka

589-0022

GSK Investigational Site, Osaka

105-0004

GSK Investigational Site, Tokyo

134-0083

GSK Investigational Site, Tokyo

185-0014

GSK Investigational Site, Tokyo

937-0066

GSK Investigational Site, Toyama